DVDaniele Vitale

Daniele Vitale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniele Vitale has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bile acids mediate liver-bone marrow crosstalk

    by Daniele Vitale, Mahmoud Karimi Azardaryany, Ghazal Alipour Talesh, Mahsa Shahidi, Vikki Ho, Suat Dervish, Fx Himawan Haryanto Jong, Maito Suo, Jacob George, Saeed Esmaili

    The modern dietary exposome is calorie dense and poor in nutritional quality resulting in high prevalence of fatty liver disease and an increasing incidence of cardiometabolic disease and cancer. We investigated the impact of dietary composition on the interaction between the liver and haematopoietic systems in mice. Using xenograft and chemical-induced liver cancer models, we find that liver tumours per se have a minimal impact on haematopoietic stem and progenitor cell (HSPC) responses. In contrast, alterations in dietary composition have profound effects on the liver-bone marrow axis. Specifically, exposure to sucrose with or without dietary cholesterol has minimal impact on the HSPC response, while perturbations in bile acid biosynthesis synergises with excess dietary cholesterol to enhance HSPC responses. Pharmacological restoration of bile acid biosynthesis partially reversed these effects. We conclude that the crosstalk between liver and bone marrow, and subsequent HSPC responses is regulated by bile acid biosynthesis.


  • Open Access

    SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants

    by Fiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, David Ross Darley, Deepti Pilli, Daniele Vitale, Vera Merheb, Fiona X. Z. Lee, Philip Cunningham, Gregory J. Walker, et al.

    The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus–cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)–confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of “high responders” maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design.